Zevra Therapeutics (ZVRA) Gross Profit (2019 - 2025)
Historic Gross Profit for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to $24.9 million.
- Zevra Therapeutics' Gross Profit rose 167967.07% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.1 million, marking a year-over-year increase of 29547.51%. This contributed to the annual value of $16.2 million for FY2024, which is 3595.78% down from last year.
- As of Q3 2025, Zevra Therapeutics' Gross Profit stood at $24.9 million, which was up 167967.07% from $13.5 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Gross Profit ranged from a high of $24.9 million in Q3 2025 and a low of $876000.0 during Q2 2024
- Over the past 5 years, Zevra Therapeutics' median Gross Profit value was $3.2 million (recorded in 2023), while the average stood at $6.9 million.
- Its Gross Profit has fluctuated over the past 5 years, first plummeted by 8875.91% in 2024, then skyrocketed by 167967.07% in 2025.
- Zevra Therapeutics' Gross Profit (Quarter) stood at $2.5 million in 2021, then decreased by 20.73% to $2.0 million in 2022, then soared by 484.65% to $11.7 million in 2023, then fell by 8.95% to $10.6 million in 2024, then soared by 133.53% to $24.9 million in 2025.
- Its Gross Profit was $24.9 million in Q3 2025, compared to $13.5 million in Q2 2025 and $19.1 million in Q1 2025.